Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohns disease
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and…
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET…
CESUR Mining Unveils Sustainable Cloud Mining Solution with Unmatched Profit Potential
London, UK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- CESUR Mining is making headlines…
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nations Health and Prosperity
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio…
West Bengal Government unveils Unlocking MSME Export Potential report prepared by Dun & Bradstreet in collaboration with MSME & Textile Department
MUMBAI, India, Feb. 13, 2025 /PRNewswire/ -- Dun & Bradstreet India, a…
Vislink Announces Delisting from Nasdaq and Potential SEC Deregistration
Mt. Olive, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Vislink Technologies, Inc.…
Bioxytrans Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)…
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to…
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to…
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to…